The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

PHASE3CompletedINTERVENTIONAL
Enrollment

12,537

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
DRUG

insulin glargine (HOE901)

Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection

DRUG

omega-3 polyunsaturated fatty acids (PUFA)

Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration

DRUG

placebo

Matching placebo gelatin capsules (containing olive oil) for oral administration

DEVICE

reusable pen device for insulin injection

Trial Locations (40)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Cove

Sanofi-Aventis Administrative Office, Vienna

Sanofi-Aventis Administrative Office, Minsk

Sanofi-Aventis Administrative Office, Hamilton

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Beijing

Sanofi-Aventis Administrative Office, Santiago de Cali

Sanofi-Aventis Administrative Office, Zagreb

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Tatari

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Mumbai

Makati City, Dublin

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Riga

Sanofi-Aventis Administrative Office, Vilnius

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Makati City

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Bucharest

Sanofi-Aventis Aministrative Office, Moscow

Sanofi-Aventis Administrative Office, Bratislava

Sanofi-Aventis Administrative Office, Midrand

Sanofi-Aventis Administrative Office, Seoul

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sanofi-Aventis Administrative Office, Geneva

Sanofi-Aventis Administrative Office, Istanbul

Sanofi-Aventis Administrative Office, Guildford

Makati City, Caracas

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

lead

Sanofi

INDUSTRY

NCT00069784 - The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) | Biotech Hunter | Biotech Hunter